This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
Study Type
OBSERVATIONAL
Enrollment
120
Novartis Investigative Site
Cairo, Cairo Governorate, Egypt
Novartis Investigative Site
Cairo, Egypt
Novartis Investigative Site
Amman, Jordan
Novartis Investigative Site
Serum Creatinine and liver enzyme levels
Observed over 3 years for each patient
Time frame: 3 years
Adverse Drug Reactions
Observed over 3 years for each patient
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Oviedo, Principality of Asturias, Spain
Novartis Investigative Site
West Midlands, Birmingham, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom